Company ProfilePremium

Singular Health Group Ltd

Company Profile Analysis

Ticker: SHG.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Singular Health Group Ltd - Company showcase

Year Founded & Workforce

2017

Singular Health Group Ltd logo

Singular Health Group Ltd Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Singular Health Group Ltd Overview

ItemDetailSource
Legal nameSingular Health Group LimitedFY2026 Annual Report
Former namesNone (Market Index records no former company names)Market Index
ABN / ACNABN 58 639 242 765 / ACN 639 242 765FY2026 Appendix 4E
FoundingTechnology origins in 2017 (MedVR, developed by Perth oncologist Dr Jason Tan)Stockhead IPO coverage, Feb 2021
Operating subsidiarySingular Health Pty Ltd, incorporated 18 September 2019FY2022 Appendix 4E
Listed parentIncorporated 20 February 2020FY2023 Annual Report, Note 1
Incorporation jurisdictionWestern Australia, Australia (public company limited by shares)FY2026 Annual Report
Registered officeLevel 5, 191 St Georges Terrace, Perth WA 6000FY2026 Annual Report
Principal place of businessE3 and E4, 661 Newcastle Street, Leederville WA 6007FY2026 Annual Report
Exchange / tickerASX: SHG (also shown as CHIA:SHG, i.e. trades on Cboe Australia)FY2026 AR; Simply Wall St
ISIN——
CUSIPNot applicable (no US listing)—
Fiscal year end30 JuneFY2026 AR
IPO12 February 2021; A$6.0M raised via 30M shares at A$0.20Squire Patton Boggs, Feb 2021
Employees (latest and 3-year trend)Not publicly disclosed. Employee benefits expense was A$3.24M in FY2026, A$1.70M in FY2025 and A$1.08M in FY2024 (continuing operations), which implies a small but growing team.FY2025 and FY2026 ARs
AuditorPitcher Partners BA&A Pty Ltd, Perth (FY2025 and FY2026; lead partner Paul Mulligan). FY2023 auditor was Nexia Perth Audit Services.FY2023, FY2025 and FY2026 ARs
Company secretarySteven Wood (Automic Group)FY2026 AR
Share registryAutomic Registry ServicesFY2026 AR
BankersNational Australia Bank (FY2025–26); ANZ (FY2023)FY2023 and FY2026 ARs
SolicitorsSquire Patton BoggsFY2026 AR
Websitehttps://singular.health; investor site https://investors.singular.healthASX announcements

Market capitalisation

ItemDetailSource
Recent quoteBid A$0.160 / offer A$0.170 at last trade on 15 Oct 2026HotCopper
Shares on issue—FY2026 AR; option exercise notices
Estimated market capitalisation~A$52–57M (analyst estimate)Derived
Earlier reference points~A$65–70M at A$0.20 (21 Jul 2026); ~A$66M (ROIC.ai)Kalkine; ROIC.ai

Singular Health is a Perth-based, US-focused micro-cap medical imaging software company. Its strategy is now centred on the 3DICOM platform, which it positions as interoperable imaging infrastructure that lets providers, payers, patients and educators locate, transfer, view and share medical scans across disparate PACS environments. The platform also renders those scans as interactive 3D models. The core commercial thesis is reducing duplicate imaging in the US healthcare system.

The company holds two FDA 510(k) Class II clearances:

  • 3DICOM MD desktop, October 2022.

  • 3DICOM MD Cloud, January 2026.

It also holds ISO 13485/MDSAP, ISO 27001, HIPAA and SOC 2 Type II credentials, and owns a proprietary Medical File Transfer Protocol (MFTP) with a favourable WIPO patentability opinion. Commercial traction remains early:

  • FY2026 contract revenue was A$1.43M, about 96% from the US, principally from one managed services organisation, Provider Network Solutions (PNS).

  • A non-binding US$2.55M Florida Medicaid repository MOU was signed on 29 September 2026.

The balance sheet is debt-free, with A$10.1M of cash and term deposits at 30 June 2026.


The company's own description (paraphrased from the FY2026 Annual Report)

The FY2026 Directors' Report defines the principal activities as:

  • development and commercialisation of the 3DICOM platform;

  • enterprise healthcare imaging and interoperability solutions;

  • education applications;

  • associated regulatory and product-development work.

The Board describes FY2026 as a year of transition from product development to commercial execution. It positions the Group as a provider of interoperable medical imaging infrastructure serving four market segments:

  • providers;

  • payers;

  • education;

  • government.

Segment reporting identifies a single operating segment: the provision and development of 3DICOM medical software (FY2026 AR, Note 4).

Independent characterisation

Singular Health is an early-commercial health-IT vendor. Its products sit at the "image exchange / zero-footprint viewer / enterprise imaging access layer" of the radiology value chain. It is not a PACS or RIS vendor, nor a diagnostic-AI developer. It overlays existing PACS through its 3DICOM Gateway and MFTP so that a primary care physician (PCP), a utilisation-management nurse at a health plan, or a patient can find and view prior studies wherever they were acquired.

The 3D volumetric rendering heritage (the original Volumetric Rendering Platform) is now a differentiating feature rather than the main value proposition. The economic pitch has shifted from "3D visualisation" to "avoid a repeat CT/MRI."

Business model and revenue model

Revenue streamMechanismFY2026 evidenceSource
Enterprise per-physician licences (subscription)Annual licence per PCP, ~US$800 per doctor per year, sold through MSOs and provider networksPNS: 750 licences deployed; US$500k licence payment received April 2026FY2026 AR; SmallCaps, Sep 2026
Pilot and implementation feesUpfront fees for bespoke pilots and integrationPNS US$300k upfront (June 2025), recognised from contract liabilitiesFY2025 AR
Government and infrastructure project fundingState-funded project delivery and operationFlorida Medicaid repository MOU: US$2.55M (A$3.5M) total, ~85% to SHG, expected to be recognised in FY2027ASX, 29 Sep 2026
Education subscriptionsInstitutional access to 3DICOM EDUMiami-Dade County Public Schools paid pilotFY2026 AR
Direct-to-consumer and clinician subscriptions (Stripe)Web subscriptions for MD, Patient and R&D tiersA$51.4k in FY2026 (A$54.8k in FY2025)FY2026 AR, Note 5
Per-transfer micro-transactionsMFTP credits (historically US$1 per scan transfer)—FY2023 AR
Non-operating supportAustralian R&D Tax Incentive refunds; interest on term depositsR&D grant income A$471.5k; interest A$444.1k (FY2026)FY2026 AR

Mix (FY2026):

  • "Product sales" recognised over time (enterprise and licence services, all US) were A$1.377M, or 96.4% of contract revenue.

  • Stripe point-in-time sales (all Australia-booked) were A$51.4k, or 3.6%.

There is no hardware revenue since the September 2024 divestment of the Singular 3DP 3D-printing business.

Value-chain position and customers

Customer typeExamplesStatus
Managed Services Organisations (MSOs) and provider networksProvider Network Solutions, Miami (serves 3.7M+ patients across Florida, Texas and Puerto Rico per FY2025 AR); Stellae Health (PNS network member)Commercial (PNS); pilot MOU (Stellae)
Health plans and payersTriple-S (Puerto Rico; GuideWell subsidiary)Strategic discussions
Diagnostic imaging centresLife Radiology, MiamiLive patient deployment; 230+ patients enrolled by 30 June 2026
EducationMiami-Dade County Public Schools (M-DCPS); Florida International University (FIU)Paid pilot; MOU
GovernmentFlorida Medicaid Imaging Repository (via FIU); a multi-million-dollar project request to the US House of Representatives (Dec-2025 quarterly)Non-binding MOU; request submitted
Individual clinicians, patients and researchersGlobal web subscribersSmall, declining share

End-markets served:

  • US healthcare (primary).

  • Australian healthcare (proof-of-concept proposals only).

  • Medical and allied-health education.

  • Historically, industrial 3D printing and mineral-resources visualisation (GeoVR); both have been exited.

Financial Narrative

Basis of the tables below:

  • Figures are taken from the audited annual reports.

  • FY2022 and FY2023 are as originally reported; FY2023 includes Singular 3DP from January 2023.

  • FY2024 is shown on the restated continuing-operations basis (FY2025 AR) for P&L lines, with net loss including discontinued operations.

  • FY2025 and FY2026 are as reported.

Income statement

Notes to the income statement table:

  • FY2021 (first, partial listed year): net loss A$4,456k; revenue and other income A$193.6k; EPS -6.02c (FY2025 AR five-year table).

  • FY2022 total revenue and other income is derived as A$54.0k revenue + A$363.7k R&D grant + A$7.6k interest. The FY2023 remuneration report shows A$54.0k for FY2022 "revenue and other income", which excludes grants.

  • FY2024 interest and finance income includes a non-cash A$302.2k unwind of convertible-note finance income.

  • Gross profit is blank where no cost of sales is reported. Software revenue carries no separately reported cost of sales, so gross margin is effectively not disclosed.

  • FY2022 and FY2023 weighted shares are derived from reported loss and EPS.

  • EBIT is derived as pre-tax income plus finance costs minus interest and finance income. EBITDA adds back D&A.

Margins and growth (%)

Revenue CAGR: contract revenue grew from A$54.0k (FY2022) to A$1,428.2k (FY2026), a 4-year CAGR of ~127%.

Balance sheet

Notes to the balance sheet table:

  • FY2021 closing cash was A$4,135.7k and closing equity A$5,082.3k (FY2023 AR comparatives).

  • FY2026 cash comprises A$2,362.0k cash at bank plus A$7,700.0k term deposits classified as financial assets.

  • FY2024 lease liabilities were partly within held-for-sale liabilities (A$261.0k), so the figure is left blank.

FY2025 net-loss typo: one FY2025 AR sentence states a net loss of A$6,736,210; the audited statements show A$6,376,210.

Cash flow

Notes to the cash flow table:

  • FY2023 borrowings comprise A$800k convertible notes plus A$419.2k R&D loan funding.

  • FY2026 receipts from customers of A$778.9k are well below recognised revenue of A$1,428.2k. The gap is explained by:

    • unwinding of the A$464.7k contract liability (cash received in FY2025);

    • a rise in receivables to A$859.4k.

  • Government grants received were nil in FY2026 versus A$354.5k in FY2025. The FY2026 R&D income of A$471.5k therefore appears to be accrued, with the cash refund expected after balance date (analyst inference from the cash flow statement).

Key ratios

ROIC, net debt/EBITDA and interest coverage are left blank because EBIT and EBITDA are negative and invested capital is negative (net cash exceeds equity less cash), so these ratios are not meaningful. FY2022 ROA is blank because FY2021 total assets were not available.

A cash conversion cycle is not meaningful for a software company with no inventory. The receivable-days figures include non-trade "other receivables" (for example, the 3DP contingent consideration), which inflates FY2025.

Commentary on trends, inflections and drivers

Revenue: an inflection from a tiny base.

  • FY2026 marks the first year of material contract revenue (A$1.43M).

  • It was driven almost entirely by the PNS Binding Enterprise Agreement:

    • recognition of the US$300k upfront payment previously held as a contract liability;

    • the US$500k licence payment received in April 2026 after deployment of 750 licences.

  • The Stripe-based direct subscription channel has been flat at roughly A$50–55k a year since FY2024. This confirms management's pivot away from direct-to-consumer towards enterprise and B2B2C channels.

Cost base: stepping up with US commercialisation.

  • Cash operating costs (payments to suppliers and employees) almost doubled, from A$3.43M in FY2025 to A$6.49M in FY2026.

  • Employee benefits rose 91% to A$3.24M, reflecting strategic hires including the US-based CCO (US$250k base salary).

  • R&D expenses rose 84% to A$1.19M.

  • Selling and marketing rose 177% to A$0.78M.

  • The reported loss was flat year on year (A$6.34M vs A$6.38M) only because non-cash share-based payments fell by A$1.18M, to A$2.09M.

Share-based payments: a structural feature.

  • Share-based payments have represented 22–51% of the annual net loss in every year since listing:

    • FY2022: A$2.66M, 44% of the loss;

    • FY2025: A$3.27M, 51%;

    • FY2026: A$2.09M, 33%.

  • This flatters cash burn relative to accounting losses but produces sustained dilution. Weighted shares rose about 3x, from 102.7M to 312.5M, between FY2022 and FY2026.

Balance sheet: transformed by FY2025 raisings.

  • In FY2023 the Group was close to insolvent:

    • equity of A$61.9k;

    • working-capital deficit of A$1.72M;

    • auditor's material-uncertainty paragraph on going concern.

  • About A$14.7M was raised in FY2025: Craig Sellars A$1.0M, the November 2024 placement A$3.7M, the June 2025 placement A$8.0M and option exercises.

  • As a result, the Group has been debt-free with A$10–14M of liquidity.

  • The FY2026 accounts no longer carry the material-uncertainty language present in FY2023 and FY2025.

Burn and runway.

  • FY2026 free cash flow was -A$5.45M, against A$10.06M of cash and term deposits at 30 June 2026. That implies roughly 22 months of runway at the FY2026 burn rate, consistent with the "about two years" runway cited in March-2026 quarterly coverage (Kalkine).

  • Potential runway extenders:

    • the US$2.55M Florida repository funding (~85% to SHG, expected in FY2027);

    • in-the-money options. About 25.3M options exercisable at A$0.08–0.10 could raise roughly A$2.2M.


7. SEGMENTAL AND GEOGRAPHIC REVENUE MAPPING

Revenue by geography: notes and sources

Source: FY2025 AR Note 5 (FY2024 continuing comparatives) and FY2026 AR Note 5.

Segment x geography

With one segment, segment-by-geography equals the geographic table above. Within revenue type, all "product sales" (enterprise and services over time) were booked in the US in FY2025 and FY2026, and all Stripe subscription revenue was booked in Australia. Stripe revenue is processed by the Australian entity regardless of where the subscriber is located; the end-customer geography of Stripe subscribers is not disclosed.

Country level, fastest-growing and declining regions

United States (fastest-growing): revenue rose to A$1.38M in FY2026.

  • The PNS network spans Florida, Texas and Puerto Rico.

  • Other reference customers and pilots sit in Miami: Life Radiology and M-DCPS. FIU is also in Miami.

  • Drivers: the MSO channel, FDA clearances, a US-based CCO and the US subsidiary.

Puerto Rico: a pilot geography under the PNS programme and the location of Triple-S. Revenue is not separately disclosed.

Australia (declining): revenue fell from A$71.7k to A$51.4k between FY2024 and FY2026. Domestic activity is limited to proof-of-concept proposals to a state agency and a radiology stakeholder group (FY2025 AR). No domestic enterprise contract has been disclosed.

Rest of world: nil since FY2025. MedVR's earlier Asian and European installed base appears to have lapsed.

Singapore: SHG Health Pte Ltd was formed in June 2026. Its purpose has not been disclosed, and no revenue has been reported.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from contracts with customers (AUD K)

54.0616.190.8203.11,428.2

R&D tax incentive / grant income (AUD K)

363.7414.2843.2354.5471.5

Interest and finance income (AUD K)

7.63.4313.8144.4444.1

Total revenue and other income, continuing (AUD K)

425.41,033.81,249.0702.02,343.9

Cost of sales (AUD K)

0514.5———

Gross profit (AUD K)

—101.6———

Employee benefits expense (AUD K)

1,718.11,825.31,078.91,699.83,240.1

Patent, R&D expenses (AUD K)

598.0587.7417.7643.81,187.3

Selling and marketing (AUD K)

290.065.6290.8282.2782.1

Share-based payments (AUD K)

2,656.11,267.11,186.13,265.12,089.7

Depreciation and amortisation (AUD K)

259.8389.1197.7129.780.9

Finance costs (AUD K)

12.9477.697.810.49.9

Operating income / EBIT, derived (AUD K)

-5,980.7-4,916.1-3,094.5-6,396.1-6,774.7

EBITDA, derived (AUD K)

-5,720.9-4,527.0-2,896.8-6,266.4-6,693.8

EBITDA excluding share-based payments, derived (AUD K)

-3,064.8-3,259.9-1,710.7-3,001.3-4,604.1

Pre-tax income, continuing (AUD K)

-5,986.0-5,390.3-2,878.4-6,262.1-6,340.5

Net income attributable to owners (AUD K)

-5,986.0-5,390.3-4,924.7-6,376.2-6,340.5

EPS basic and diluted (A$ cents)

-5.83-4.90-3.08-2.69-2.03

Dividends per share (A$ cents)

00000

Weighted average shares, basic (millions)

102.7110.0160.1237.0312.5

Margin metric

Margin metricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

—16.5———

Operating (EBIT) margin, derived (%)

-11,076-798-3,408-3,149-474

EBITDA margin, derived (%)

-10,594-735-3,190-3,085-469

Net margin, continuing loss / revenue (%)

-11,085-875-3,170-3,083-444

Revenue growth YoY, contract revenue (%)

—1,041—124603

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD K)

2,140.22,998.62,350.814,207.511,235.9

Cash, equivalents and term deposits (AUD K)

1,139.9691.51,453.413,678.610,062.0

Trade and other receivables, current (AUD K)

141.576.262.6319.6859.4

Short-term borrowings (AUD K)

1.12,236.0218.500

Long-term borrowings (AUD K)

0139.6000

Lease liabilities, total (AUD K)

84.5134.9—0110.0

Net debt / (net cash), incl. leases (AUD K)

-1,054.31,819.0-1,234.9-13,678.6-9,952.0

Goodwill and intangibles (AUD K)

454.51,046.5113.700

Total liabilities (AUD K)

391.52,936.7909.61,111.0699.2

Contract liabilities / deferred revenue (AUD K)

06.64.5464.70

Total equity (AUD K)

1,748.761.91,441.213,096.610,536.7

Issued capital (AUD K)

9,526.711,977.616,430.829,919.432,656.2

Accumulated losses (AUD K)

-11,149.7-16,137.5-20,903.6-23,877.9-30,218.4

Working capital (AUD K)

936.7-1,720.9653.512,953.810,407.1

Net tangible assets per share (A$ cents)

——0.684.343.26

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Receipts from customers (AUD K)

54.0688.11,094.4638.7778.9

Operating cash flow (AUD K)

-2,905.8-2,463.2-2,440.3-2,341.4-5,302.4

Capex: PP&E (AUD K)

11.822.573.629.2143.8

Free cash flow, derived (AUD K)

-2,917.6-2,485.7-2,513.8-2,370.5-5,446.2

Equity issued, gross proceeds (AUD K)

01,553.95,168.414,716.01,694.9

Borrowings raised (AUD K)

01,219.2811.700

Borrowings repaid (AUD K)

0.402,482.8205.10

Dividends paid (AUD K)

00000

Share buybacks (AUD K)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE, net loss / average equity, derived (%)

-175-595-655-88-54

ROA, net loss / average assets, derived (%)

—-210-184-77-50

Current ratio (x)

3.500.362.4212.6618.19

Debt / equity, incl. leases (x)

0.0540.560.1500.01

Asset turnover, revenue / average assets (x)

—0.240.030.020.11

Receivable days, current receivables / revenue x 365 (days)

—45252574220

Income Statement

Region (AUD K)FY2024FY2025FY2026

United States of America

0148.31,376.8

Australia

71.754.851.4

Rest of world

19.100

Total contract revenue

90.8203.11,428.2

Margin Analysis (%)

Region metricFY2024FY2025FY2026

US share of revenue (%)

073.096.4

Australia share of revenue (%)

79.027.03.6

US revenue growth YoY (%)

——828

Australia revenue growth YoY (%)

—-24-6

Share price metric

Share price metricFY2022FY2023FY2024FY2025FY2026

Share price at fiscal year end (AUD)

0.0960.0360.100.380.21

Year-on-year change in FYE share price (%)

-69-63178280-45

Share Price & Returns

PeriodPerformanceBasis

1-year

About -45%

~A$0.30 (20 Oct 2025, InvestSMART release price) to ~A$0.165 (15 Oct 2026). Kalkine cited about -46% over the year to 21 Jul 2026.

3-year

About +300% or more

~A$0.039 (15 Aug 2023 close, cited in the CG1 placement) to ~A$0.165

5-year

About -47% vs 30 Jun 2021; about -18% vs IPO price

—

52-week range

A$0.17 – A$0.345

As of 4 Sep 2026 (StockAnalysis); recent bids at A$0.16 suggest new lows

Valuation Multiples

MultipleSHGPro Medicus (reference)Mach7 (reference)

Market cap

~A$52–57M (estimated)

~A$20bn (StockAnalysis)

—

Enterprise value

~A$42–47M (market cap less A$10.06M cash and term deposits)

——

P/E

Not meaningful (loss)

Not computed

Not meaningful (loss)

EV/EBITDA

Not meaningful (negative EBITDA)

Not computed

Not computed

EV/Sales (FY2026)

~30–33x

~76x on market cap / FY2026 revenue (cash not deducted)

Not computed

P/B

~5.0–5.4x (equity A$10.54M)

Not computed

Not computed

Price to book (StockAnalysis/PrimeStockFinder at A$0.18)

4.86x——

Capital Markets

ItemDetail

Dividend history and policy

No dividend has ever been paid or declared (FY2021–FY2026); none is expected while the company is loss-making

Buybacks

None authorised or executed

Credit ratings

None (Moody's, S&P and Fitch do not rate the company)

Debt maturity profile

No borrowings. Lease liabilities of A$110.0k (A$16.1k current; A$93.9k non-current) at 30 Jun 2026. Convertible notes and R&D loans were fully repaid by FY2025.

Capital Instruments

InstrumentNumberTerms

Unlisted options

76,752,772

Exercise prices A$0.08 – A$0.55; expiries Feb 2027 – Nov 2029

of which A$0.08

17,562,500

Expire 8 Dec 2027

of which A$0.10

7,727,272

Expire 9 Feb 2027

of which A$0.15

18,463,000

Expire Jul 2027 – Feb 2028

of which A$0.25

17,000,000

Expire Apr 2028 – Apr 2029

of which A$0.55

16,000,000

Expire Jun 2028 – Nov 2029

Performance rights

10,000,000

CEO; vested; expire 30 Jun 2028

Share Price & Returns by Date

DateRaisePrice (AUD)

Feb 2021

IPO A$6.0M

0.20

Aug 2022

Convertible notes A$0.8M

—

Apr–May 2023

Placement A$1.45M

~0.055

Aug 2023

CG1 strategic placement A$0.5–0.85M

0.055

Feb 2024

Placement A$4.05M

—

Jul 2024

Sellars A$1.0M

—

Nov 2024

Placement A$3.7M

0.09

Jun 2025

Placement A$8.0M

0.35

Catalyst Details

CatalystExpected timingWhy it matters

PNS licence renewal and expansion

Overdue (was due Q3 CY2026)

Core recurring revenue

Definitive Florida Medicaid repository agreement and first cash receipts

FY2027 (H1 CY2027 likely)

Converts the MOU into binding revenue

Triple-S (or other payer) contract

Undated

First health-plan logo; validates the UM/RBM thesis

AGM (late 2026)

Per notice of 6 Oct 2026

Remuneration and option resolutions; board renewal

Sep-2026 and Dec-2026 quarter Appendix 4C reports

Late Oct 2026; late Jan 2027

Receipts versus burn

Stellae Health pilot outcomes

FY2027

PNS-network replication

M-DCPS cohort results and conversion to ARR

FY2027

Education vertical; the STI KPI is more than US$300k ARR

HITRUST certification

Undated

Enterprise payer procurement requirement

MFTP national-phase grants

Rolling

IP defensibility

Option exercises (A$0.08 tranche expiring Dec 2027)

Through 2027

Non-dilutive-equivalent funding of ~A$1.4M

H1 FY2027 Appendix 4D

Feb 2027

First half including SIS-US consolidation

Executive Leadership

Board of Directors

NameRoleTenureBackgroundEducationOther listed boards

Howard Digby

Non-Executive Chairman

Board since listing (fees reported from 27 Jan 2021)

IBM; senior roles at Adobe and Gartner; 12 years in Hong Kong, ending as Regional MD of The Economist Group; former Executive Editor, WA Business News; consultant to Forrest Capital

BEng (Hons), University of Western Australia

Elsight (ELS), 4DS Memory (4DS); formerly Spenda (resigned 21 Nov 2024)

Denning Chong

Managing Director and CEO; co-founder

Director since incorporation; NED until 14 Apr 2023; Interim CEO/MD from 14 Apr 2023; Executive Service Agreement from 15 Apr 2023

Principal of James Chong Lawyers since 2004 (cross-border transactions and M&A); director of Mutual Limited (fund manager, >A$4bn FUM), Australian subsidiaries of SGX-listed Hiap Hoe, and Aloft Hotel Perth

LLB (Dist.), BCom

—

Andrew Just

Non-Executive Director

Board since listing era

Former Regional Director Asia Pacific, Radiometer (Danaher); CEO of Aeris Environmental; 30 years with GE Healthcare, Danaher, Stryker and Cochlear

BEc, HEc, MBA, GAICD

—

Executive Leadership Team

NameRoleTenure / notesSource

Dr Martina Mariano (PhD)

Chief Operating Officer

CCO 9 Feb 2024 – 28 Feb 2025; COO from 1 Feb 2025. Earlier Global Partnerships Manager; led US conference outreach in 2022. Base salary A$230k for FY2026.

FY2025 and FY2026 ARs

Paige Taylor

Chief Commercial Officer (US)

From 15 Sep 2025. Base US$250k; CY2026 target bonus of 100% of base; 3M options promised (strike no lower than A$0.55), not yet granted at 30 Jun 2026.

FY2026 AR

Andre Rocha

Chief Quality Officer

Led the MD Cloud 510(k) submission

ASX, 28 Nov 2025

Steven Wood

Company Secretary

Principal at Automic Group; previously Grange Consulting

FY2026 AR

Dr Ronny Low

Technical Advisor (radiologist)

Dec 2024

FY2025 AR

Dr Alex Alonso

US radiology adviser; founder of Life Radiology. Paid in shares (US$27k fee settled in shares at the 14-day VWAP after six months).

Jul 2025

FY2025 AR

Executive Leadership Team — Thomas Hanly

NameFormer roleExit / notes

Thomas Hanly

CEO and MD

Departed 14 Apr 2023

Prof. Kwang Guan Tay

Executive Director, Innovation & Research

Resigned 24 Mar 2023

James Hill

COO

Resigned 27 Jun 2025 (employed from 4 Nov 2019)

Sujana Karthik

CFO and Joint Company Secretary

Appointed May 2023 (Grange Consulting)

Kyla Garic

CFO

FY2024–FY2025, services via Onyx Corporate. Not listed as KMP in FY2026.

Directors' Remuneration

NameSalary and feesCash bonusAnnual leaveSuperShare-basedTotal

Howard Digby (NE Chair)

72,500008,70060,089141,289

Andrew Just (NED)

62,500007,50060,089130,089

Denning Chong (MD/CEO)

250,000135,00030,59230,0001,051,9651,497,557

Martina Mariano (COO)

220,000024,37326,4000270,773

Paige Taylor (CCO, from 15 Sep 2025)

293,0670000293,067

James Hill (resigned 27 Jun 2025; leave payout)

14,526003,974018,500

Total KMP

912,593

135,000

54,965

76,574

1,172,143

2,351,275

Related-Party Transactions

CounterpartyRelationshipAmountsSource

James Chong & Co Pty Ltd

Associated with the CEO; legal services

A$5,309 (FY2026); A$9,042 (FY2025); A$50,959 (FY2023)

FY2023, FY2025 and FY2026 ARs

Onyx Corporate (Kyla Garic)

CFO services

A$124,872 (FY2025)

FY2025 AR

Re-Energise Digital (James Hill)

Marketing services

A$14,146 (FY2025)

FY2025 AR

Marin & Sons Strategies LLC

Substantial holder and US adviser

2,785,416 shares issued for consulting at A$0.305 (10 Sep 2025). Sold 4,166,667 SIS-US shares to SHG for US$175k (30 Jul 2026).

FY2026 AR

Board & Management Changes

DateChange

1 Feb 2025

Mariano becomes COO

27 Jun 2025

Hill resigns as COO

15 Sep 2025

Taylor appointed CCO (US)

19 Nov 2025

AGM approves 6M new CEO options

Major Shareholders

HolderShares% (approx.)Source / date

Marin and Sons Strategies LLC

20,618,407

6.77% (substantial holder notice, 22 Aug 2025); ~6.6% (Simply Wall St)

InvestSMART; Simply Wall St, Nov 2025

Denning Chong (incl. indirect)

17,429,719

~5.4–5.6%

FY2026 AR; Simply Wall St

Klosters Holdings Pty Ltd

8,150,000

~2.6%

Simply Wall St, Nov 2025

Chong Cheong

7,065,754

~2.3%

Simply Wall St, Nov 2025

JLI Enterprises Pty Ltd

6,640,869

~2.1%

Simply Wall St, Nov 2025

Ilia Manolev

5,988,577

~1.9%

Simply Wall St, Nov 2025

Gaja Enterprises Ltd

5,555,556

~1.8%

Simply Wall St, Nov 2025

Martina Mariano (COO)

1,602,505

~0.5%

FY2026 AR

Howard Digby (Chair)

722,275

~0.2%

FY2026 AR

Andrew Just (NED)

336,364

~0.1%

FY2026 AR

Targets & Commitments

InitiativeDateDescription / status

PNS strategic partnership

Nov 2024 – present

Four-phase programme: proof of concept, then pilot planning, then pilot, then national rollout. 750 licences deployed; contract renewal was due Q3 CY2026, with the outcome not yet disclosed.

Cloud re-platforming

Mar 2024 – FY2025

Complete migration to a zero-footprint cloud; UI/UX redesign; new clinical viewer aligned with diagnostic viewers

3DICOM Gateway and Submission Portal

FY2025

Hardware-free PACS connectivity

Divestment of non-core 3DP

Sep–Oct 2024

Focus on software

US corporate build-out

Jul 2025 – Jul 2026

US LLC formed; CCO hired; SIS-US joint vehicle with PNS (30%, stepped to ~60%)

MD Cloud FDA clearance

Nov 2025 – Jan 2026

Achieved in 40 days

Payer expansion (Triple-S)

FY2025 – FY2026

Enterprise imaging platform proposal covering Gateway, MD, Patient, AI-in-the-Cloud and UM/RBM workflows

Provider reference site (Life Radiology)

Jul 2025 – present

Gateway plus Patient; 230+ patients enrolled

Education (M-DCPS, FIU)

Mar 2026 – present

Paid pilot across five technical colleges for up to 150 students and instructors; FIU evaluation MOU

Florida Medicaid Imaging Repository

FY2026 – Sep 2026

Amended MOU: US$2.55M; 85% SHG share; five-year Florida-Medicaid exclusivity; follow-on annual state funding sought (FIU intends to seek more than US$3M a year)

Federal outreach

Dec-2025 quarter

Multi-million-dollar project request submitted to the US House of Representatives; participation in the ONC consultation on diagnostic imaging interoperability

HITRUST certification

FY2026 – ongoing

In progress

Talk2View CRC-P application

FY2026

AI-assisted visual communication integration; outcome uncertain

athenahealth Marketplace

Dec-2025 quarter

Integration explored

Stellae Health pilot

Post-FY2026

Eight primary care practices within the PNS network

Competitive Landscape

Key Competitors

CompetitorTypeOverlap with SHGScale / financials (where verified)

Pro Medicus (ASX: PME), Visage 7

Listed, Australia/US

Enterprise cloud-native diagnostic viewing in large US health systems

FY2026 revenue A$261.7M (+22.9%); underlying NPAT A$144.7M; underlying EBIT A$196.1M; cash and term deposits A$252.3M (FY2026 results, Aug 2026)

Mach7 Technologies (ASX: M7T)

Listed, Australia/US

Vendor-neutral archive (VNA), enterprise viewer and image orchestration

FY2026 revenue A$27.9M (-17%); loss A$8.9M; 84% recurring revenue; cash A$19.9M (FY2026 results)

PocketHealth (Toronto, private)

VC-backed

Patient-centric image exchange; community gateways; directly comparable to 3DICOM Patient and Gateway

US$33M Series B (2024); more than C$75M equity raised; 600+ hospitals and imaging centres; consumer subscription model (Goodmans; TechCrunch)

Intelerad (private; includes Ambra Health and Life Image)

PE-backed

Cloud image exchange and enterprise imaging

—

Nuance PowerShare (Microsoft)

Big-tech subsidiary

Legacy image exchange network

—

Change Healthcare / Optum (UnitedHealth)

Payer-owned IT

Image exchange and RBM-adjacent workflows

—

Purview (private)

Private

Image sharing and zero-footprint viewer

—

Philips, GE HealthCare, Siemens Healthineers (enterprise imaging)

Multinational OEMs

Enterprise PACS, VNA and cloud viewers bundled with modalities

—

Materialise (Mimics) and Synopsys Simpleware

Listed / segment

3D segmentation and surgical planning (overlaps the legacy R&D tier)

—

3D Systems (VSP), Axial3D

Listed / private

Virtual surgical planning and 3D anatomical modelling

—

Free and low-cost DICOM viewers (OsiriX/Horos, RadiAnt, Weasis)

Open-source / low-cost

Clinician and patient viewing

—

“—” = not publicly disclosed.

Peer Comparison FY2026

Metric (FY2026)Singular Health (SHG)Pro Medicus (PME)Mach7 (M7T)

Revenue (AUD Mn)

1.43261.727.9

Revenue growth YoY (%)

507 (reported) / 603 (continuing)

22.9-17.4

EBIT / operating margin (%)

-474 (derived)

~75 (underlying EBIT / revenue)

Loss-making

Net margin (%)

-444

55 (underlying NPAT basis)

-32

R&D intensity (%)

83 (reported R&D line only)

——

Cash and deposits (AUD Mn)

10.1252.319.9

Recent Developments

April – December 2025

DateEventSignificance
15 Apr 2025Issue of incentive options to the CEO (10M at A$0.25) and NEDs, following GM approval on 19 Mar 2025Equity incentive alignment; dilution
19 Jun 2025US$1.3M Binding Enterprise Agreement with PNS; A$8M placement at A$0.35First binding enterprise contract; transformational recapitalisation
26 Jun 2025Quotation of 22.4M placement shares and 1.58M shares from conversionsCompletes placement tranche
27 Jun 2025COO James Hill resignsKey-person change; Mariano already COO
3 Jul 2025Dr Alex Alonso appointed US radiology adviser; Life Radiology deploymentUS clinical credibility; reference site
4 Jul & 7 Aug 2025US subsidiaries formedUS operating platform
25 Jul 2025CEO buys A$100k of shares on market (~A$0.33)Insider confidence
18 Aug 2025SIS-US incorporated (SHG 30%, alongside PNS entities)JV structure with anchor customer
22 Aug 2025Marin and Sons Strategies becomes a substantial holder (6.77%)US adviser becomes the largest holder
29 Aug 2025FY2025 results: loss A$6.38M; cash and term deposits A$13.7MStrong balance sheet
10 Sep 20252,785,416 shares issued to Marin & Sons for consulting at A$0.305Share-settled adviser fees
15 Sep 2025Paige Taylor appointed US CCOUS commercial leadership
20 Oct 2025September-quarter Appendix 4COperational update
19 Nov 2025AGM: remuneration report passes (93.04%); 6M CEO options approvedGovernance
28 Nov 2025FDA 510(k) submission for 3DICOM MD CloudRegulatory catalyst
Dec-2025 quarter250 MD licences deployed to PNS; Life Radiology moves from pilot to full patient deployment; next-generation Mobile app released; US House project request; athenahealth integration explored; operations continued through the US government shutdownCommercial deployment begins
22 Dec 2025CEO exercises 1.82M options at A$0.10Insider capital injection

January – June 2026

DateEventSignificance
13 Jan 2026FDA 510(k) clearance for 3DICOM MD Cloud (40-day review; adds X-ray and ultrasound)Second FDA clearance; enables the cloud subscription model; shares rose more than 15% intraday (Webull)
19–20 Jan 20261.72M options exercised at A$0.20 (A$344k; 12-month voluntary escrow)Capital
27 Jan 2026December-quarter Appendix 4CPipeline update; Florida MOU targeted by mid-2026
24 Feb 2026H1 FY2026 results: revenue +345%; net loss A$2.97M (+55%), including A$1.01M share-based paymentsCost step-up evident
Mar 2026500 more licences deployed (750 total); Life Radiology Patient go-live; M-DCPS paid pilot executed; FIU MOU signedMulti-vertical progress
18 Mar 2026Chair buys A$10k of shares on market (~A$0.24)Insider signal (small)
9 Apr 2026Cleansing notice and option-exercise quotationsCapital
22 Apr 2026US$500k licence payment received from PNSFirst material cash licence receipt
28 Apr 2026March-quarter Appendix 4C: cash A$10.015M, about two years' runwayLiquidity
1 & 14 May 2026Further option exercises (~0.78M at A$0.10)Minor capital
10 Jun 2026Shares fall 7.3% to A$0.19 on thin volume with no newsIlliquidity
12 Jun 2026SHG Health Pte Ltd (Singapore) incorporatedPossible Asia vehicle (purpose undisclosed)
23–29 Jun 2026Option exercises, including 2.57M at A$0.10 (26 Jun)Capital

July – October 2026

DateEventSignificance
16 Jul & 17 Aug 2026Further option exercises and quotationsCapital
21 Jul 2026Shares fall ~9.1% to ~A$0.20; down ~46% over 12 monthsSentiment weakness
30 Jul 2026SIS-US stake lifted to ~60% for US$175k; control obtainedConsolidation of the PNS-aligned vehicle
31 Jul 2026June-quarter Appendix 4C: cash and term deposits ~A$10.1M; M-DCPS cohort for SeptemberLiquidity and pipeline
28–31 Aug 2026FY2026 Appendix 4E and Annual Report: revenue A$1.43M (+507%); loss A$6.34M. Appendix 4G and Corporate Governance Statement lodged 31 Aug.Results
29 Sep 2026Amended MOU with FIU: US$2.55M (A$3.5M) Florida Medicaid Imaging Repository; ~85% to SHG; five-year Florida-Medicaid exclusivity; IP retainedLargest single revenue opportunity to date, roughly 2x FY2026 revenue; non-binding
30 Sep 2026Notice under ASX Listing Rule 3.13.1 (AGM date and director nominations). HotCopper also lists an Appendix 4E/Annual Report item dated 30 Sep 2026, likely a re-lodgement of the full report.Corporate calendar
1 Oct 2026Company presentation; investor webinar noticeInvestor relations
6 Oct 2026Notice of AGM and proxy formAGM approaching (date in notice)
8 Oct 2026Investor webinar (COO Martina Mariano) on the Florida MOU and operationsInvestor relations
Post-FY2026Stellae Health pilot MOU (eight practices)PNS network expansion
~15 Oct 2026Last trade ~A$0.16–0.17Shares near 52-week lows

Disclosure gaps

the outcome of the PNS licence renewal (due Q3 CY2026);

the Triple-S decision;

definitive Florida agreements.

litigation;

guidance revisions;

layoffs;

regulatory enforcement.

Company Snapshot

2017

Founded

Leederville, Australia

Headquarters

SWOT Analysis

Strengths

  • Dual FDA 510(k) clearances: MD desktop on 27 Oct 2022 (70-day review) and MD Cloud in Jan 2026 (40-day review), the latter expanding to X-ray and ultrasound (FY2023 AR; ASX 13 Jan 2026).
  • Debt-free balance sheet with A$10.06M of cash and term deposits at 30 June 2026, and working capital of A$10.41M (FY2026 AR).
  • Commercial validation by a paying US MSO: 750 licences deployed and a US$500k licence payment received in April 2026 (FY2026 AR).
  • Enterprise-grade compliance stack: ISO 13485, MDSAP, ISO 27001, HIPAA and SOC 2 Type II. An independent threat assessment found no critical or high-risk issues (FY2026 AR).
  • Patentable core protocol: a favourable WIPO IPRP for MFTP, with national phase in nine jurisdictions (FY2026 AR).
  • Strong revenue momentum from a small base: contract revenue rose 603% on a continuing basis, to A$1.43M (FY2026 AR).
  • Aligned strategic shareholders: PNS (equity holder and SIS-US co-owner), Marin & Sons (6.77%) and the CEO (~5.5%), with recent insider buying (FY2026 AR; InvestSMART).

Weaknesses

  • Customer concentration: 96.4% of FY2026 revenue came from the US, overwhelmingly through PNS (FY2026 AR, Note 5).
  • Persistent losses: accumulated losses of A$30.2M against cumulative issued capital of A$32.7M (FY2026 AR).
  • Cash burn doubled: operating cash outflow rose from A$2.34M (FY2025) to A$5.30M (FY2026).
  • Heavy reliance on share-based compensation: A$2.09M in FY2026 and A$3.27M in FY2025. The CEO's FY2026 package was 78% LTI by value (FY2026 AR).
  • Thin governance structures: a three-person board with no separate committees in FY2026 (FY2026 AR, section 3).
  • Weak cash conversion: FY2026 customer receipts of A$0.78M were 55% of recognised revenue, and receivables tripled to A$0.86M (FY2026 AR).
  • History of strategic churn: MedVR, VisualEyes, GeoVR, 3D printing (Global3D) and Surgical were all launched and then discontinued between 2021 and 2024 (IPO materials; FY2023–FY2025 ARs).

Opportunities

  • Florida Medicaid Imaging Repository: US$2.55M of initial funding (~2x FY2026 revenue), with FIU seeking more than US$3M a year of follow-on funding (ASX 29 Sep 2026; SmallCaps).
  • National Medicaid replication: 66.7M members, with the Florida model positioned as a blueprint (Bulls n' Bears, Sep 2026).
  • Payer expansion: Triple-S enterprise platform proposal covering UM and RBM workflows (FY2026 AR).
  • PNS network expansion: the remaining 250 licences of the 1,000 contracted; affiliated MSOs; the Stellae Health pilot (FY2026 AR).
  • Education vertical: M-DCPS is the third-largest US public school district (TipRanks, Jul 2026). FIU is an academic partner.
  • EHR marketplace distribution (athenahealth) and RIS/LIS/EHR connectors (Dec-2025 quarterly; FY2026 AR).
  • AI and imaging-data commercialisation through the repository and the AI framework (Stockhead, Aug 2026).

Threats

  • Well-funded private competitor: PocketHealth (more than C$75M raised, 600+ sites) targets the same patient-access and gateway use case (Goodmans, 2024).
  • Incumbent networks: Optum/Change Healthcare and Microsoft/Nuance PowerShare (TechCrunch, Mar 2024).
  • Government funding risk: the Florida MOU is non-binding and dependent on state appropriations (ASX, 29 Sep 2026).
  • Contract renewal risk: the PNS licence arrangement was due to expire in Q3 CY2026, with renewal under discussion at year end (FY2026 AR).
  • Dilution overhang: 76.75M options and 10M performance rights outstanding, about 26% of shares (FY2026 AR, sections 12–13).
  • Market sentiment and liquidity: the shares fell about 46% over the year to July 2026, with large moves on thin volume (Kalkine, Jun–Jul 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
15 Apr 2025Issue of incentive options to the CEO (10M at A$0.25) and NEDs, following GM approval on 19 Mar 2025Equity incentive alignment; dilution
19 Jun 2025US$1.3M Binding Enterprise Agreement with PNS; A$8M placement at A$0.35First binding enterprise contract; transformational recapitalisation
26 Jun 2025Quotation of 22.4M placement shares and 1.58M shares from conversionsCompletes placement tranche
27 Jun 2025COO James Hill resignsKey-person change; Mariano already COO
3 Jul 2025Dr Alex Alonso appointed US radiology adviser; Life Radiology deploymentUS clinical credibility; reference site
4 Jul & 7 Aug 2025US subsidiaries formedUS operating platform
25 Jul 2025CEO buys A$100k of shares on market (~A$0.33)Insider confidence
18 Aug 2025SIS-US incorporated (SHG 30%, alongside PNS entities)JV structure with anchor customer
22 Aug 2025Marin and Sons Strategies becomes a substantial holder (6.77%)US adviser becomes the largest holder
29 Aug 2025FY2025 results: loss A$6.38M; cash and term deposits A$13.7MStrong balance sheet
10 Sep 20252,785,416 shares issued to Marin & Sons for consulting at A$0.305Share-settled adviser fees
15 Sep 2025Paige Taylor appointed US CCOUS commercial leadership
20 Oct 2025September-quarter Appendix 4COperational update
19 Nov 2025AGM: remuneration report passes (93.04%); 6M CEO options approvedGovernance
28 Nov 2025FDA 510(k) submission for 3DICOM MD CloudRegulatory catalyst
Dec-2025 quarter250 MD licences deployed to PNS; Life Radiology moves from pilot to full patient deployment; next-generation Mobile app released; US House project request; athenahealth integration explored; operations continued through the US government shutdownCommercial deployment begins
22 Dec 2025CEO exercises 1.82M options at A$0.10Insider capital injection
13 Jan 2026FDA 510(k) clearance for 3DICOM MD Cloud (40-day review; adds X-ray and ultrasound)Second FDA clearance; enables the cloud subscription model; shares rose more than 15% intraday (Webull)
19–20 Jan 20261.72M options exercised at A$0.20 (A$344k; 12-month voluntary escrow)Capital
27 Jan 2026December-quarter Appendix 4CPipeline update; Florida MOU targeted by mid-2026
24 Feb 2026H1 FY2026 results: revenue +345%; net loss A$2.97M (+55%), including A$1.01M share-based paymentsCost step-up evident
Mar 2026500 more licences deployed (750 total); Life Radiology Patient go-live; M-DCPS paid pilot executed; FIU MOU signedMulti-vertical progress
18 Mar 2026Chair buys A$10k of shares on market (~A$0.24)Insider signal (small)
9 Apr 2026Cleansing notice and option-exercise quotationsCapital
22 Apr 2026US$500k licence payment received from PNSFirst material cash licence receipt
28 Apr 2026March-quarter Appendix 4C: cash A$10.015M, about two years' runwayLiquidity
1 & 14 May 2026Further option exercises (~0.78M at A$0.10)Minor capital
10 Jun 2026Shares fall 7.3% to A$0.19 on thin volume with no newsIlliquidity
12 Jun 2026SHG Health Pte Ltd (Singapore) incorporatedPossible Asia vehicle (purpose undisclosed)
23–29 Jun 2026Option exercises, including 2.57M at A$0.10 (26 Jun)Capital
16 Jul & 17 Aug 2026Further option exercises and quotationsCapital
21 Jul 2026Shares fall ~9.1% to ~A$0.20; down ~46% over 12 monthsSentiment weakness
30 Jul 2026SIS-US stake lifted to ~60% for US$175k; control obtainedConsolidation of the PNS-aligned vehicle
31 Jul 2026June-quarter Appendix 4C: cash and term deposits ~A$10.1M; M-DCPS cohort for SeptemberLiquidity and pipeline
28–31 Aug 2026FY2026 Appendix 4E and Annual Report: revenue A$1.43M (+507%); loss A$6.34M. Appendix 4G and Corporate Governance Statement lodged 31 Aug.Results
29 Sep 2026Amended MOU with FIU: US$2.55M (A$3.5M) Florida Medicaid Imaging Repository; ~85% to SHG; five-year Florida-Medicaid exclusivity; IP retainedLargest single revenue opportunity to date, roughly 2x FY2026 revenue; non-binding
30 Sep 2026Notice under ASX Listing Rule 3.13.1 (AGM date and director nominations). HotCopper also lists an Appendix 4E/Annual Report item dated 30 Sep 2026, likely a re-lodgement of the full report.Corporate calendar
1 Oct 2026Company presentation; investor webinar noticeInvestor relations
6 Oct 2026Notice of AGM and proxy formAGM approaching (date in notice)
8 Oct 2026Investor webinar (COO Martina Mariano) on the Florida MOU and operationsInvestor relations
Post-FY2026Stellae Health pilot MOU (eight practices)PNS network expansion
~15 Oct 2026Last trade ~A$0.16–0.17Shares near 52-week lows

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Income Statement: Revenue & Gross Profit: Total revenue and other income, continuing rose from AUD 0.4 Mn in FY2022 to AUD 2.3 Mn in FY2026.
Singular Health Group Ltd — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Total revenue and other income, continuing0.411.20.72.3
Revenue from contracts with customers0.10.60.10.21.4
Cost of sales00.5———
Gross profit—0.1———

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.